Halozyme Therapeutics
(NASDAQ) HALO
Halozyme Therapeutics Financials at a Glance
Market Cap
$7.27B
Revenue (TTM)
$1.40B
Net Income (TTM)
$316.89M
EPS (TTM)
$2.49
P/E Ratio
24.73
Dividend
$0.00
Beta (Volatility)
0.79 (Low)
Dividend
$0.00
Beta (Volatility)
0.79 (Low)
Price
$61.69
Volume
38,178
Open
$62.96
Price
$61.69
Volume
38,178
Open
$62.96
Previous Close
$61.69
Daily Range
$61.35 - $63.16
52-Week Range
$47.50 - $82.22
Dividend
$0.00
Beta (Volatility)
0.79 (Low)
Price
$61.69
Volume
38,178
Open
$62.96
Previous Close
$61.69
Daily Range
$61.35 - $63.16
52-Week Range
$47.50 - $82.22
HALO News
HALO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Halozyme Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
423
CEO
Helen I. Torley, MD
Website
www.halozyme.comHeadquarters
San Diego, CA 92121, US
HALO Financials
Key Financial Metrics (TTM)
Gross Margin
82%
Operating Margin
58%
Net Income Margin
23%
Return on Equity
154%
Return on Capital
35%
Return on Assets
13%
Earnings Yield
4.04%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$7.27B
Shares Outstanding
118.02M
Volume
38.18K
Short Interest
0.00%
Avg. Volume
1.85M
Financials (TTM)
Gross Profit
$1.09B
Operating Income
$816.29M
EBITDA
$904.34M
Operating Cash Flow
$651.56M
Capital Expenditure
$6.97M
Free Cash Flow
$644.59M
Cash & ST Invst.
$142.82M
Total Debt
$0.00
Halozyme Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$451.77M
+51.6%
Gross Profit
$349.62M
+36.6%
Gross Margin
77.39%
N/A
Market Cap
$7.27B
N/A
Market Cap/Employee
$20.78M
N/A
Employees
350
N/A
Net Income
$141.59M
-203.3%
EBITDA
$281.08M
+38.3%
Quarterly Fundamentals
Net Cash
$142.82M
+115.7%
Accounts Receivable
$441.27M
+43.1%
Inventory
$176.47M
+24.4%
Long Term Debt
$0.00
-100.0%
Short Term Debt
$0.00
N/A
Return on Assets
12.55%
N/A
Return on Invested Capital
34.76%
N/A
Free Cash Flow
$217.60M
+24.0%
Operating Cash Flow
$219.03M
+22.7%